| A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable A Cortellini, M Bersanelli, S Buti, K Cannita, D Santini, F Perrone, R Giusti, ... Journal for immunotherapy of cancer 7, 1-11, 2019 | 335 | 2019 |
| Clinical outcomes of patients with advanced cancer and pre‐existing autoimmune diseases treated with anti‐programmed death‐1 immunotherapy: a real‐world transverse study A Cortellini, S Buti, D Santini, F Perrone, R Giusti, M Tiseo, M Bersanelli, ... The oncologist 24 (6), e327-e337, 2019 | 153 | 2019 |
| Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients A Cortellini, R Chiari, B Ricciuti, G Metro, F Perrone, M Tiseo, M Bersanelli, ... Clinical lung cancer 20 (4), 237-247. e1, 2019 | 137 | 2019 |
| Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/Programmed cell death … A Cortellini, M Bersanelli, D Santini, S Buti, M Tiseo, K Cannita, F Perrone, ... European Journal of Cancer 128, 17-26, 2020 | 95 | 2020 |
| Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and … S Buti, M Bersanelli, F Perrone, M Tiseo, M Tucci, V Adamo, LS Stucci, ... European Journal of Cancer 142, 18-28, 2021 | 85 | 2021 |
| The prognostic role of high blood cholesterol in advanced cancer patients treated with immune checkpoint inhibitors F Perrone, R Minari, M Bersanelli, P Bordi, M Tiseo, E Favari, R Sabato, ... Journal of Immunotherapy 43 (6), 196-203, 2020 | 41 | 2020 |
| Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy S Buti, M Bersanelli, F Perrone, S Bracarda, M Di Maio, R Giusti, O Nigro, ... European Journal of Cancer 150, 224-231, 2021 | 27 | 2021 |
| First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis F Facchinetti, M Di Maio, F Perrone, M Tiseo Translational Lung Cancer Research 10 (6), 2917, 2021 | 26 | 2021 |
| Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review SE Rebuzzi, F Perrone, M Bersanelli, G Bregni, M Milella, S Buti Expert Review of Molecular Diagnostics 20 (2), 169-185, 2020 | 24 | 2020 |
| Exploring the role of respiratory microbiome in lung cancer: A systematic review F Perrone, L Belluomini, M Mazzotta, M Bianconi, V Di Noia, F Meacci, ... Critical Reviews in Oncology/Hematology 164, 103404, 2021 | 20 | 2021 |
| Palliative radiotherapy in advanced cancer patients treated with immune‑checkpoint inhibitors: the PRACTICE study M Bersanelli, E Lattanzi, N D'Abbiero, S Buti, A Leonetti, MG Canè, ... Biomedical Reports 12 (2), 59-67, 2020 | 14 | 2020 |
| Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study A Cortellini, S Buti, M Bersanelli, R Giusti, F Perrone, P Di Marino, N Tinari, ... Oncoimmunology 9 (1), 1710389, 2020 | 9 | 2020 |
| Systemic thromboembolism from a misdiagnosed non‑bacterial thrombotic endocarditis in a patient with lung cancer: A case report F Perrone, A Biagi, F Facchinetti, F Bozzetti, A Ramelli, A Vezzani, ... Oncology letters 20 (5), 1-1, 2020 | 8 | 2020 |
| Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy M Bersanelli, T Zielli, F Perrone, C Casartelli, F Prattico, E Rapacchi, ... Immunotherapy 12 (15), 1139-1148, 2020 | 7 | 2020 |
| Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring BRAF Mutations: Focus on Clinical Characteristics and Treatment Outcome … F Perrone, G Mazzaschi, R Minari, M Verzè, C Azzoni, L Bottarelli, ... Cancers 14 (8), 2019, 2022 | 6 | 2022 |
| Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP) A Passaro, GL Russo, F Passiglia, M D'Arcangelo, A Sbrana, M Russano, ... Lung Cancer 174, 118-124, 2022 | 5 | 2022 |
| Differential diagnosis of COVID-19 at the chest computed tomography scan: A review with special focus on cancer patients F Perrone, M Balbi, C Casartelli, S Buti, G Milanese, N Sverzellati, ... World Journal of Radiology 13 (8), 243, 2021 | 5 | 2021 |
| Review on radiological evolution of COVID-19 pneumonia using computed tomography C Casartelli, F Perrone, M Balbi, V Alfieri, G Milanese, S Buti, M Silva, ... World Journal of Radiology 13 (9), 294, 2021 | 3 | 2021 |
| Therapeutic Outcomes and Clinical Features of Advanced Non–Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study G Mazzaschi, F Perrone, R Minari, M Verzè, C Azzoni, L Bottarelli, ... Clinical Lung Cancer 23 (7), e478-e488, 2022 | 1 | 2022 |
| Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study S Buti, F Perrone, T Zielli, G Mazzaschi, C Casartelli, A Leonetti, ... Clinical Medicine Insights: Oncology 15, 11795549211043427, 2021 | 1 | 2021 |
